ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The conventional treatment for CML, before the development of tyrosine kinase inhibitor (TKI) therapy targeting BCR-ABL1, included splenic radiotherapy, nonspecific chemotherapeutics (interferon-alpha, hydroxyurea), and allogeneic stem cell transplantation [5,6].